Acting Attorney General Issues New DEA Order Reclassifying Some Marijuana Products as Schedule III Controlled Substances, Available by Prescription

Why It Matters

The rescheduling creates a federally recognized pathway for medical marijuana, impacting compliance, tax treatment, and employee accommodation across regulated industries.

Key Takeaways

• Six million new users can present state medical certifications for workplace accommodation
• DEA registration now required for state‑licensed dispensaries to access federal system
• Prescribers must follow controlled‑substance rules, aligning marijuana with Schedule III drugs
• DOT testing regime faces uncertainty as medical marijuana gains federal prescription status

Pulse Analysis

On April 23, 2026, Acting Attorney General Todd Blanche signed a final order that moves FDA‑approved cannabis medicines and state‑licensed medical marijuana products from Schedule I to Schedule III of the Controlled Substances Act. The shift acknowledges therapeutic value while still imposing strict prescribing and dispensing requirements. By classifying these products as Schedule III, the DEA can now track them through its registration system, and researchers gain clearer pathways to obtain plant material for clinical studies. The move fulfills a long‑standing demand from the pharmaceutical sector for a federal framework that mirrors state medical programs.

For employers, the order creates a new class of legally protected drug use. Approximately six million patients who previously relied on informal state certifications will now hold federally recognized prescriptions, giving them a documented defense against positive drug tests. Companies must revise drug‑testing policies, especially in industries governed by the Department of Transportation, where marijuana remains a prohibited substance for safety‑sensitive positions. While the DOT’s Omnibus Transportation Employee Testing Act is unlikely to change immediately, firms should prepare to evaluate accommodation requests on a case‑by‑case basis and ensure that any medical‑marijuana use does not impair job performance.

The rescheduling is not without political resistance; at least 20 Republican senators have voiced opposition, and some states, such as Oklahoma, are tightening employment protections. A public hearing slated for June 29, 2026 will further shape implementation details. Employers should monitor the DEA’s six‑month review timeline for state license registrations and anticipate potential guidance from the Equal Employment Opportunity Commission on reasonable accommodations. In the interim, clear communication, updated compliance training, and a proactive stance on policy revision will help organizations navigate the evolving legal landscape.